Table 3.
Biomarkers at each time point (baseline and following QST) by group (matched SCD patients and healthy matched controls). nMean (SD)
| BL | 3 | 4 | 5 | 6 | 7 | |
|---|---|---|---|---|---|---|
| Multiplex | ||||||
| IFNγ-SCD | 2710.5 (11.6) | 2311.0 (14.4) | 2312.1 (17.1) | 2311.9 (17.3 | 178.6 (7.4) | 129.2 (10.1) |
| IFNγ-HC | 235.5 (7.1) | 225.4 (6.3) | 225.0 (5.7) | 225.2 (5.9) | 214.5 (5.2) | 214.5 (5.3) |
| IL1B-SCD | 220.03 (0.04) | 180.03 (0.04) | 180.02 (0.04) | 180.03 (0.05) | 130.03 (0.04) | 100.05 (0.07) |
| IL1B-HC | 110.03 (0.03) | 110.03 (0.04) | 100.05 (0.05) | 110.04 (0.04) | 100.17 (0.41) | 90.41 (0.96) |
| IL2-SCD | 260.23 (0.35) | 220.20 (0.33) | 220.24 (0.31) | 220.21 (0.25) | 160.12 (0.13) | 110.12 (0.08) |
| IL2-HC | 230.16 (0.13) | 220.13 (0.14) | 220.13 (0.14) | 220.14 (0.11) | 210.15 (0.13) | 210.13 (0.12) |
| IL4-SCD | 250.02 (0.02) | 200.02 (0.02) | 200.02 (0.02) | 200.03 (0.03) | 140.03 (0.03) | 90.03 (0.02) |
| IL4-HC | 180.02 (0.02) | 160.02 (0.02) | 160.02 (0.02) | 160.03 (0.03) | 160.03 (0.03) | 150.02 (0.02) |
| IL6-SCD | 260.7 (0.74) | 220.8 (0.4) | 221.0 (0.5) | 221.5 (2.1) | 171.3 (0.5) | 121.7 (0.9) |
| IL6-HC | 230.5 (0.3) | 220.6 (0.3) | 220.7 (0.4) | 220.8 (0.4) | 211.1 (0.8) | 211.2 (0.9) |
| IL8-SCd | 278.5 (4.8) | 237.6 (6.4) | 2312.1 (15.2) | 2310.9 (13.0) | 1713.4 (6.9) | 1119.8 (34.8) |
| IL8-HC | 234.0 (2.1) | 224.1 (2.4) | 224.0 (2.3) | 224.3 (2.0) | 216.6 (10.3) | 216.6 (10.9) |
| IL-10-SCD | 270.4 (0.2 | 230.4 (0.3) | 230.4 (0.3) | 230.4 (0.3) | 170.5(0.4) | 120.4 (0.3) |
| IL-10-HC | 230.2 (0.1) | 220.2 (0.1) | 220.2 (0.1) | 220.2 (0.1) | 210.2 (0.1) | 210.2 (0.1) |
| IL-12 | 270.1 (0.1) | 230.2 (0.1) | 230.2 (0.1) | 230.2 (0.1) | 170.2 (0.1) | 110.2 (0.1) |
| IL-12-HC | 230.2 (0.2) | 220.2 (0.2) | 220.2 (0.2) | 220.2 (0.1 | 210.2 (0.1 | 210.2 (0.2 |
| IL-13-SCD | 261.1 (0.8) | 221.1 (0.9) | 221.4 (0.8) | 221.3 (0.8) | 161.3 (0.9) | 121.5 (1.2) |
| IL13-HC | 230.9 (0.9) | 220.8 (1.0) | 220.9 (0.8) | 220.9 (1.0) | 211.0 (1.0) | 210.9 (1.0) |
| Single Assays | ||||||
| TNFα-SCD | 272.1 (1.0) | 222.1 (1.1) | 232.2 (1.1) | 212.2 (1.0) | 172.3 (1.3) | 112.5(1.4) |
| TNFα-HC | 271.3 (1.1) | 251.3 (0.9) | 261.3 (0.9) | 251.4 (1.0) | 251.3 (1.0) | 251.3 (1.0) |
| NPY-SCD | 2714.3 (7.0) | 2315.2 (8.1) | 2315.2 (8.7) | 2215.7 (7.5) | 1913.7 (8.9) | 1610.4 (10.1) |
| NPY-HC | 2319.3 (6.1) | 2221.0 (6.9) | 2220.6 (6.2) | 2221.1 (6.6) | 2122.1 (6.5) | 2121.2 (6.9) |
| ET-SCD | 271.4 (0.4) | 231.6 (0.5) | 231.8 (0.5) | 211.9 (0.6) | 172.0 (0.7) | 112.0 (0.6) |
| ET-HC | 231.8 (0.5) | 222.0 (0.6) | 222.2 (0.8) | 222.2 (0.7) | 212.3 (0.7) | 212.4 (0.8) |
| SP-SCD |
27343.2 (188.3) |
23367.6 (192.5) |
23391.4 (203.8) |
22375.1 (188.5) |
17337.6 (172.5) |
11349.5 (112.0) |
| SP-HC |
23415.0 (754.5) |
22481.2 (874.5) |
22493.8 (859.3) |
22498.6 (859.8) |
21514.7 (902.6) |
21477.0 (738.0) |
IFN-γ: Interferon gamma, IL: Interleukin, TNFα: Tumor necrosis factor alpha, NPY: Neuropeptide Y, ET: Endothelium, SP: Substance P. All measures are reported as sample size n in superscript (n) mean (SD).